CN105228627B - 亮氨酸和烟酸降低脂质水平 - Google Patents

亮氨酸和烟酸降低脂质水平 Download PDF

Info

Publication number
CN105228627B
CN105228627B CN201480027603.9A CN201480027603A CN105228627B CN 105228627 B CN105228627 B CN 105228627B CN 201480027603 A CN201480027603 A CN 201480027603A CN 105228627 B CN105228627 B CN 105228627B
Authority
CN
China
Prior art keywords
niacin
composition
leucine
metabolites
nicotinamide riboside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480027603.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105228627A (zh
Inventor
麦克·泽梅尔
安提亚·布鲁克鲍尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nusirt Sciences Inc
Original Assignee
Nusirt Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nusirt Sciences Inc filed Critical Nusirt Sciences Inc
Publication of CN105228627A publication Critical patent/CN105228627A/zh
Application granted granted Critical
Publication of CN105228627B publication Critical patent/CN105228627B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
CN201480027603.9A 2013-03-15 2014-03-13 亮氨酸和烟酸降低脂质水平 Expired - Fee Related CN105228627B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800363P 2013-03-15 2013-03-15
US61/800,363 2013-03-15
PCT/US2014/026816 WO2014152016A1 (en) 2013-03-15 2014-03-13 Leucine and nicotinic acid reduces lipid levels

Publications (2)

Publication Number Publication Date
CN105228627A CN105228627A (zh) 2016-01-06
CN105228627B true CN105228627B (zh) 2018-07-13

Family

ID=51581094

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480027603.9A Expired - Fee Related CN105228627B (zh) 2013-03-15 2014-03-13 亮氨酸和烟酸降低脂质水平

Country Status (16)

Country Link
US (5) US9585876B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968333B1 (cg-RX-API-DMAC7.html)
JP (2) JP6550370B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150130455A (cg-RX-API-DMAC7.html)
CN (1) CN105228627B (cg-RX-API-DMAC7.html)
AU (1) AU2014236687A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023310A2 (cg-RX-API-DMAC7.html)
CA (1) CA2902879C (cg-RX-API-DMAC7.html)
HK (1) HK1219660A1 (cg-RX-API-DMAC7.html)
IL (1) IL240762B (cg-RX-API-DMAC7.html)
MX (1) MX2015011195A (cg-RX-API-DMAC7.html)
PH (1) PH12015502033A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015143836A (cg-RX-API-DMAC7.html)
SG (1) SG11201507046UA (cg-RX-API-DMAC7.html)
WO (1) WO2014152016A1 (cg-RX-API-DMAC7.html)
ZA (4) ZA201506481B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108261547A (zh) 2011-07-15 2018-07-10 纽斯尔特科学公司 用于调节代谢途径的组合物和方法
JP6469015B2 (ja) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド エネルギー代謝を増大させるための組成物および方法
JP6550370B2 (ja) 2013-03-15 2019-07-24 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
AU2015222754B2 (en) 2014-02-27 2020-06-25 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
EP3174891B1 (en) 2014-07-24 2020-01-29 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
WO2016049236A1 (en) * 2014-09-24 2016-03-31 Nusirt Sciences, Inc. Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
CN107428791B (zh) 2015-03-09 2024-05-28 格雷斯公司 烟酰胺核苷的结晶形式
CN107531738B (zh) 2015-03-16 2021-02-19 可劳迈戴斯有限公司 烟酸核苷或烟酰胺核苷组合物、其还原衍生物及其用途
WO2017213486A2 (es) * 2016-06-08 2017-12-14 Astudillo De La Vega Horacio Combinación de reguladores metabólicos bioenergéticos y nutra-epigenéticos, compuestos nutracéuticos en combinaciónes convencionales y nanotecnológicas para revertir y prevenir la sesencencia celular acelerada por daño crónico producida por diabetes y otras enfermedades complejas crónico-degenerativas
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
CA3030740C (en) * 2016-07-19 2021-11-02 Roland W. Winterfield Use of beta-hydroxy beta-methylbutyrate in combination with leucic acid for alleviating statin side effects
US12370159B2 (en) 2016-10-21 2025-07-29 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics
DK3528801T3 (da) * 2016-10-21 2024-10-14 Metabolic Tech Llc Præparater og fremgangsmåder til anvendelse af beta-hydroxy-beta-methylbutyrat (HMB) og probiotika
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
BR112019010607B1 (pt) 2016-11-29 2023-10-31 University Of Iowa Research Foundation Uso de precursores de nad e composição compreendendo os referidos precursores
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
SE540582C2 (en) * 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
US20210177875A1 (en) * 2017-12-01 2021-06-17 Elysium Health, Inc. Methods and compositions for treating childhood or teen obesity
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE
WO2019133815A1 (en) * 2017-12-28 2019-07-04 Kansas State University Research Foundation Nicotinamide riboside treatments of domesticated meat animals
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
US10568352B1 (en) 2018-10-25 2020-02-25 Wiser Concepts, LLC Nutritional compositions and methods of treatment therewith
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
US11547693B2 (en) 2019-07-29 2023-01-10 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
CN116019780B (zh) * 2021-10-26 2024-09-24 成都拂尔医药科技有限公司 一种双黄纳米颗粒及其制备与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130017283A1 (en) * 2011-07-15 2013-01-17 Michael Zemel Compositions and methods for modulating metabolic pathways

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3936527A (en) 1969-12-19 1976-02-03 Damon Corporation Treatment of pets
US3810994A (en) 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
NL7804375A (nl) 1977-05-16 1978-11-20 Ralston Purina Co Voedsel voor dieren.
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4769027A (en) 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
IE58246B1 (en) 1984-12-21 1993-08-11 Byk Gulden Lomberg Chem Fab Theophylline sustained release formulation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5087624A (en) 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
GB8919131D0 (en) 1989-08-23 1989-10-04 Riker Laboratories Inc Inhaler
US4992470A (en) 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5419283A (en) 1992-04-08 1995-05-30 Ciuffo Gatto S.R.L. Animal chew toy of starch material and degradable ethylene copolymer
JP3219838B2 (ja) 1992-05-12 2001-10-15 沖電気工業株式会社 半導体素子の製造方法
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
LU88369A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Acides aminés à chaînes ramifiées
US5339771A (en) 1993-09-15 1994-08-23 Axelrod Herbert R Animal chew toy containing animal meal
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
US5616569A (en) 1994-03-28 1997-04-01 The Iams Company Pet food product containing fermentable fibers and process for treating gastrointestinal disorders
US6048903A (en) 1994-05-03 2000-04-11 Robert Toppo Treatment for blood cholesterol with trans-resveratrol
US5776913A (en) 1995-10-10 1998-07-07 Colgate Palmolive Company Therapeutic diet for metabolic abnormalities found in animals with lymphoma
WO1997025060A1 (en) 1996-01-09 1997-07-17 The Institute Of Physical And Chemical Research Amino acid compositions
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
PT862863E (pt) 1997-01-09 2002-04-29 Nestle Sa Produto cerealifero contendo probioticos
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6063414A (en) 1997-08-18 2000-05-16 Seal Rock Technologies Incorporated Combination container and dry pet food for increased shelf life, freshness, palatability, and nutritional value
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
CN1305485A (zh) 1998-05-04 2001-07-25 安德里斯·约翰尼斯·凯塞尔 单体,寡聚和多聚科诺威纳格尔缩合产物
US6387419B1 (en) 1998-06-02 2002-05-14 Biofiber-Damino A/S Piglet feeding method
US6031000A (en) 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US6403142B1 (en) 1998-12-11 2002-06-11 Ralston Purina Company Hypoallergenic pet food
NZ512410A (en) 1998-12-17 2003-02-28 Alza Corp Controlled release liquid filled gelatin capsules comprising barrier, expandable and superpermeable layers and an orifice
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
BR0008857A (pt) 1999-03-08 2001-12-18 Medicure Inc Análogos de piridoxal para distúrbios da vitaminab-6
FR2790645B1 (fr) 1999-03-12 2001-06-08 Arkopharma Laboratoires Complement alimentaire et procede de traitement cosmetique a base d' un extrait de raisin riche en polyphenols
WO2001021165A1 (en) 1999-09-21 2001-03-29 Rutgers, The State University Resveratrol analogs for prevention of disease
US6527711B1 (en) 1999-10-18 2003-03-04 Bodymedia, Inc. Wearable human physiological data sensors and reporting system therefor
US6280779B1 (en) 1999-12-28 2001-08-28 Colgate-Palmolive Company Pet food for maintaining normal bowel health
JP2003529347A (ja) 2000-01-25 2003-10-07 ジュヴェノン インコーポレイテッド 高齢ペット用の栄養補給食品
US6605038B1 (en) 2000-06-16 2003-08-12 Bodymedia, Inc. System for monitoring health, wellness and fitness
US7261690B2 (en) 2000-06-16 2007-08-28 Bodymedia, Inc. Apparatus for monitoring health, wellness and fitness
BRPI0414359A (pt) 2000-06-16 2006-11-14 Bodymedia Inc sistema para a monitoração e gerenciamento do peso corpóreo e demais condições psicológicas que abrangem um planejamento interativo e personalizado, intervenção e capacidade de formular relatórios
US7689437B1 (en) 2000-06-16 2010-03-30 Bodymedia, Inc. System for monitoring health, wellness and fitness
US20020165237A1 (en) 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
US6384087B1 (en) 2000-09-01 2002-05-07 University Of Tennesseee Research Corporation, Inc. Materials and methods for the treatment or prevention of obesity
EP1345500B1 (en) 2000-12-29 2008-07-30 Martin Francis Gannon An animal food product
WO2002071874A2 (en) 2001-03-09 2002-09-19 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
US6338862B1 (en) 2001-03-26 2002-01-15 Sarfaraz K Niazi Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors
US6595929B2 (en) 2001-03-30 2003-07-22 Bodymedia, Inc. System for monitoring health, wellness and fitness having a method and apparatus for improved measurement of heat flow
US7091006B2 (en) 2001-11-09 2006-08-15 Dana-Farber Cancer Institute, Inc. PGC-1β, a novel PGC-1 homologue and uses therefor
US20030187055A1 (en) 2002-02-25 2003-10-02 Riker Donald K. Synergistic pharmaceutical combinations for treating obesity
KR20110043664A (ko) 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
CN100453130C (zh) 2002-06-26 2009-01-21 精达制药公司 用于渗透性药物传递系统的最低顺应性和高容积效率的活塞
FR2841784B1 (fr) 2002-07-08 2007-03-02 Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
US7020508B2 (en) 2002-08-22 2006-03-28 Bodymedia, Inc. Apparatus for detecting human physiological and contextual information
BR0315184A (pt) 2002-10-09 2005-08-30 Bodymedia Inc Método e aparelho para auto-acompanhamento de estados corporais contìnuos ou discretos utilizando parâmetros fisiológicos e/ou contextuais
US20050064070A1 (en) 2002-10-11 2005-03-24 Jeffrey Liebrecht Beverage compositions for use in rehydration and nutrition during athletic exercise and methods of making same
US7744930B2 (en) 2002-11-22 2010-06-29 Shaklee Corporation Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
JP2004305201A (ja) 2002-11-27 2004-11-04 Hayashibara Biochem Lab Inc アクリルアミドの生成抑制方法とその用途
CN1504424A (zh) 2002-12-05 2004-06-16 上海金创投资管理有限公司 含亮氨酸婴儿饮用水
US20040254357A1 (en) 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
US7288570B2 (en) 2002-12-20 2007-10-30 Nutricia N.V. Stimulation of in vivo production of proteins
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
CA2518735C (en) 2003-03-13 2012-05-15 Vector Usa Inc. A film having a liquid absorbed therein
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
CN100415224C (zh) 2003-03-18 2008-09-03 诺瓦提斯公司 包含脂肪酸和氨基酸的组合物
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
US20050042362A1 (en) 2003-04-02 2005-02-24 Clark Harry M. Pet food composition and method
DK1638586T3 (da) 2003-05-14 2008-06-23 Indus Biotech Pvt Ltd Synergistisk sammensætning til behandling af diabetes mellitus
WO2005003766A2 (en) 2003-06-13 2005-01-13 Whitehead Institute For Biomedical Research Methods of regulating metabolism and mitochondrial function
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
JP2005097273A (ja) 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
KR101084554B1 (ko) 2003-09-12 2011-11-17 보디미디어 인코퍼레이티드 심장 관련 파라미터를 측정하기 위한 방법 및 장치
ES2402427T3 (es) 2003-11-03 2013-05-03 Hill's Pet Nutrition Inc. Composición de alimento recubierto para animales de compañía
WO2005049618A1 (en) 2003-11-19 2005-06-02 Dsm Ip Assets B.V. Manufacture of vitamin b6
JPWO2005049006A1 (ja) 2003-11-21 2007-11-29 味の素株式会社 糖尿病治療剤
CA2546286C (en) 2003-11-26 2012-10-02 Hill's Pet Nutrition, Inc. Method to reduce odor of excreta from companion animals
CA2548671C (en) 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
JP2008503475A (ja) 2004-06-17 2008-02-07 フォーレスト ラボラトリーズ， インコーポレイテッド メマンチンの放出が改変された製剤
US20070244202A1 (en) 2004-06-28 2007-10-18 Kao Corporation Ampk Activator
WO2006023603A2 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20080004335A1 (en) 2004-11-29 2008-01-03 Kinya Takagaki Athletic Ability Enhancing Composition
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20060165824A1 (en) 2005-01-26 2006-07-27 The Procter & Gamble Company Compositions, kits, and methods for enhancing gastrointestinal health
ATE421325T1 (de) 2005-02-11 2009-02-15 Argenta Discovery Ltd Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
US20060188611A1 (en) 2005-02-18 2006-08-24 Emine Unlu Edible pet chew
US20090163476A1 (en) 2005-03-03 2009-06-25 Sirtris Pharmaceuticals, Inc. N-Phenyl Benzamide Derivatives as Sirtuin Modulators
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EA014643B1 (ru) 2005-05-13 2010-12-30 Нестек С.А. Способ получения растительного сырья, обогащенного глюкозамином, и растительный экстракт, обогащенный глюкозамином
EP1898890A1 (en) 2005-06-16 2008-03-19 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
JP2009500357A (ja) * 2005-07-07 2009-01-08 サートリス ファーマシューティカルズ， インコーポレイテッド 肥満、インスリン抵抗性障害およびミトコンドリア関連障害を処置または予防するための方法および関連する組成物
JP2007039367A (ja) * 2005-08-02 2007-02-15 Kyoto Univ 細胞の分化を促進する組成物およびその利用
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
PL1910384T3 (pl) 2005-08-04 2013-03-29 Sirtris Pharmaceuticals Inc Pochodne imidazo[2,1-b]tiazolu jako związki modulujące sirtuinę
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US20070077310A1 (en) 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
AU2006320167C1 (en) 2005-12-02 2011-04-07 Hill's Pet Nutrition, Inc. Methods for altering stool quality and/or stool frequency
CN103445019A (zh) 2006-01-10 2013-12-18 希尔氏宠物营养品公司 用于促进脂肪减少的组合物和方法
WO2007100695A2 (en) 2006-02-28 2007-09-07 Trustees Of Boston University Metabolic regulators and uses thereof
DE102006016903A1 (de) 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalator
US20090182036A1 (en) 2006-05-10 2009-07-16 Krammer-Lukas Stephanie J M Animal food composition comprising genistein and polyunsaturated fatty acids
JP2007306851A (ja) 2006-05-18 2007-11-29 仁 ▲吉▼井 食塩組成物およびその製造方法
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
US20090291958A1 (en) 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
DK2038252T3 (en) 2006-07-12 2016-12-19 Univ Tennessee Res Found SUBSTITUTED AND ACYLANILIDER methods of use thereof
ITRM20060427A1 (it) 2006-08-04 2008-02-05 Nuraging Biotech S R L Composizioni antiossidanti comprendenti estratti di rosmarino e mirto
JP5507802B2 (ja) 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
US8703174B2 (en) 2006-09-15 2014-04-22 I Did It Inc Joint preserving nutritional vitamin, mineral and herbal pet supplement
US20080102137A1 (en) * 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
AU2007341981A1 (en) 2006-12-29 2008-07-10 The Salk Institute For Biological Studies Methods for enhancing exercise performance
US8431552B2 (en) 2007-01-16 2013-04-30 Chien-Hung Chen Composition for treating metabolic syndrome
US20080320029A1 (en) 2007-02-16 2008-12-25 Stivoric John M Lifeotype interfaces
CA2678807C (en) 2007-02-23 2012-07-17 Hill's Pet Nutrition, Inc. Compositions and methods for controlling the weight of animals
WO2008115563A1 (en) 2007-03-19 2008-09-25 University Of Florida Research Foundation, Inc. Liquid nutrient composition for improving performance
US20080242727A1 (en) 2007-03-27 2008-10-02 Tim Romero Dietary compositions containing alpha amino n-butyrate and methods of enhancing lean body mass
US20100210692A1 (en) 2007-03-28 2010-08-19 Farmer Stephen R Methods of treatment using sirt modulators and compositions containing sirt1 modulators
US20080268038A1 (en) 2007-04-26 2008-10-30 Wolfe Robert R Compositions and Approaches for Increasing Diet Induced Thermogenesis, Inducing Weight Loss and Maintaining Muscle Mass and Strength
US20080286254A1 (en) 2007-05-17 2008-11-20 Kaneka Corporation Composition comprising licorice polyphenol
EP2167043A4 (en) 2007-06-06 2013-05-01 Univ South Florida NEW USE CO-CRYSTAL COMPOSITIONS
US20090054450A1 (en) 2007-06-19 2009-02-26 Ironwood Pharmaceuticals, Inc. Compositions and methods of use for treating or preventing lipid related disorders
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US7989007B2 (en) 2007-07-03 2011-08-02 Vincent James Enterprises, Llc Weight loss composition
WO2009003798A1 (en) 2007-07-05 2009-01-08 Unilever N.V. Food composition comprising trans-resveratrol and its use to control blood pressure
EP2170338A2 (en) 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
US8529965B2 (en) 2007-07-09 2013-09-10 Hill's Pet Nutrition, Inc. Compositions and methods for altering stool quality in an animal
WO2009033034A1 (en) 2007-09-07 2009-03-12 Nike, Inc. Wearable device assembly having athletic functionality
JP2011500810A (ja) 2007-10-23 2011-01-06 プレジデント アンド フェロウズ オブ ハーバード カレッジ 運動を模倣するためのｓｉｒｔ−３関連方法及び組成物
US20090156648A1 (en) 2007-12-12 2009-06-18 Iovate T. & P. Inc. Preparations containing pyridoxine and alpha-hydroxyisocaproic acid (HICA)
RU2440771C1 (ru) 2007-12-21 2012-01-27 Хилл'С Пет Ньютришн, Инк. Состав кормового продукта для домашних животных (варианты)
US8716249B2 (en) * 2008-01-31 2014-05-06 Energy Light Llc Compositions and methods for improving cardiovascular health
JP5525456B2 (ja) 2008-02-04 2014-06-18 マーキュリー セラピューティクス，インコーポレイテッド Ａｍｐｋ調節因子
JP5643116B2 (ja) 2008-03-03 2014-12-17 ナイキ イノベイト セー． フェー． 対話型運動器具システム
CN101965170B (zh) 2008-03-17 2013-06-12 宝洁公司 用户可定制的剂量体系
WO2009124193A1 (en) 2008-04-02 2009-10-08 Nike, Inc. Wearable device assembly having athletic functionality
CN102088978B (zh) 2008-07-07 2013-12-18 持田制药株式会社 血脂异常症的改善或治疗药
US20100021573A1 (en) 2008-07-22 2010-01-28 Michael J Gonzalez Compositions and methods for the prevention of cardiovascular disease
US8835490B2 (en) 2008-08-15 2014-09-16 Nestec Sa Methods for enhancing energy metabolism
WO2010065567A2 (en) 2008-12-01 2010-06-10 Lifespan Extension Llc Methods and compositions for altering health, wellbeing, and lifespan
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
CA2760158C (en) 2009-04-26 2016-08-02 Nike International Ltd. Gps features and functionality in an athletic watch system
US20100303967A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food Having Improved Animal Preference
US20100303966A1 (en) 2009-05-28 2010-12-02 Gregory Dean Sunvold Pet Food in the Form of a Coated Kibble
WO2011003045A1 (en) 2009-07-01 2011-01-06 Magceutics, Inc. Slow release magnesium composition and uses thereof
US20120129785A1 (en) 2009-07-21 2012-05-24 Hill's Pet Nutrition, Inc. Companion animal nutrition system
US8691303B2 (en) 2009-07-31 2014-04-08 The Iams Company Dusted animal food
US20110064720A1 (en) 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
KR20120081605A (ko) 2009-09-18 2012-07-19 폴리페놀레스 나투랄레스, 에스.엘. 푸코잔틴 및 퓨닉산의 결합물에 의해 시르투인 효소를 활성화시켜 노화 과정을 지연시키는 방법
WO2011051974A1 (en) 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
US8173181B2 (en) 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
RU2012132481A (ru) 2009-12-29 2014-02-10 Хилл`С Пет Ньютришн, Инк. Композиции для животных-компаньонов, включающие пируват, и способы их применения
US20120301559A1 (en) 2010-01-06 2012-11-29 Sylvie Pridmore-Merten Dietary regimens useful for mimicking caloric restrictions
US20110208153A1 (en) 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
US8663716B2 (en) 2010-04-28 2014-03-04 Nihon Pharmaceutical Co., Ltd. Composition for treatment of aesthenopia
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102077936B (zh) 2010-09-20 2013-04-24 王强 一种糖尿病患者专用的海洋特膳食品
US9167991B2 (en) 2010-09-30 2015-10-27 Fitbit, Inc. Portable monitoring devices and methods of operating same
HRP20201731T1 (hr) 2011-01-07 2020-12-25 Anji Pharma (Us) Llc Terapije na bazi liganda kemozensoričkog receptora
WO2012097064A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
EP2744356A4 (en) * 2011-08-19 2015-05-27 Musclepharm Corp COMPOSITIONS AND METHODS FOR INHIBITING INCOUNTERANCE IN ANIMALS
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR101409330B1 (ko) 2012-05-11 2014-06-18 안국약품 주식회사 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
JP6469015B2 (ja) 2012-11-13 2019-02-13 ニューサート サイエンシーズ， インコーポレイテッド エネルギー代謝を増大させるための組成物および方法
EP2945616B1 (en) 2013-01-15 2018-11-28 NuSirt Sciences, Inc. Treating pulmonary conditions
AU2014238377A1 (en) 2013-03-15 2015-09-10 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators
JP6550370B2 (ja) 2013-03-15 2019-07-24 ニューサート サイエンシーズ， インコーポレイテッド 脂質レベルを低下させるロイシンおよびニコチン酸
US20160213639A1 (en) 2013-10-07 2016-07-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2015222754B2 (en) 2014-02-27 2020-06-25 Nusirt Sciences Inc. Compositions and methods for the reduction or prevention of hepatic steatosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130017283A1 (en) * 2011-07-15 2013-01-17 Michael Zemel Compositions and methods for modulating metabolic pathways

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Interrelationships of leucine with lysine, tryptophan, and niacin as they influence protein value of cereal grains for humans;Constance Kies et al.;《Cereal Chemistry》;19720430;第223-231页 *

Also Published As

Publication number Publication date
JP2016516040A (ja) 2016-06-02
MX2015011195A (es) 2016-03-11
US20170000780A1 (en) 2017-01-05
ZA201506481B (en) 2017-08-30
US9707213B2 (en) 2017-07-18
WO2014152016A1 (en) 2014-09-25
EP2968333A1 (en) 2016-01-20
CA2902879A1 (en) 2014-09-25
US20150056274A1 (en) 2015-02-26
US20170340615A1 (en) 2017-11-30
ZA201805629B (en) 2019-11-27
PH12015502033A1 (en) 2016-01-18
US9408834B2 (en) 2016-08-09
EP2968333B1 (en) 2022-01-12
AU2014236687A1 (en) 2015-09-10
CN105228627A (zh) 2016-01-06
HK1219660A1 (zh) 2017-04-13
JP2019065049A (ja) 2019-04-25
KR20150130455A (ko) 2015-11-23
US20180214421A1 (en) 2018-08-02
RU2015143836A (ru) 2017-04-27
ZA201705790B (en) 2018-12-19
US20160008329A1 (en) 2016-01-14
US9895357B2 (en) 2018-02-20
IL240762A0 (en) 2015-10-29
BR112015023310A2 (pt) 2017-07-18
JP6550370B2 (ja) 2019-07-24
SG11201507046UA (en) 2015-10-29
EP2968333A4 (en) 2016-11-02
CA2902879C (en) 2023-09-26
US9585876B2 (en) 2017-03-07
IL240762B (en) 2018-11-29
ZA201606052B (en) 2018-05-30

Similar Documents

Publication Publication Date Title
CN105228627B (zh) 亮氨酸和烟酸降低脂质水平
US20180235917A1 (en) Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
CN104918610B (zh) 用于增强能量代谢的组合物和方法
EP2731599B1 (en) Compositions and methods for modulating metabolic pathways
US10039733B2 (en) Compositions, method, and kits for treating pulmonary conditions
KR20160119863A (ko) 간 지방증의 감소 또는 예방을 위한 조성물 및 방법
US20220409647A1 (en) Compositions, methods and kits for altering adipocytes
ES3036279T3 (en) Food supplements comprising propolis
HK1217169B (en) Treating pulmonary conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180713

Termination date: 20210313

CF01 Termination of patent right due to non-payment of annual fee